Gluten-related disorders

1. A method of treating a subject having a gluten-related disorder, the method comprising:

administering to the subject an effective amount of a composition comprising a probiotic bacterium Lactobacillus paracasei CBA L74, deposited at the Belgian Coordinated Collections of Micro-organisms (BCCM) Laboratorium voor Microbiologie (LMG) and having International Depository Accession Number LMG P-24778, wherein the probiotic bacterium reduces a symptom of gliadin peptide toxicity.

2. The method of claim 1 , wherein the gliadin peptide is an α-gliadin peptide.

3. The method of claim 2 , wherein the α-gliadin peptide has an amino acid sequence selected from the group consisting of LGQQQPFPPQQPY (SEQ ID NO: 1); QLQPFPQPQLPY (SEQ ID NO: 2); LGQQQPFPPQQPYPQPQPF (SEQ ID NO: 3); and LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 4).

4. The method of claim 1 , wherein the gluten-related disorder is celiac disease or gluten sensitivity.

5. The method of claim 1 , wherein the symptom of gliadin peptide toxicity comprises at least one of inflammation, an autoimmune reaction, a gastrointestinal symptom, weight loss, anemia, osteoporosis, arthritis, infertility, peripheral neuropathy, and liver failure.

6. The method of claim 1 , further comprising a step of administering a second treatment for the gluten-related disorder.

7. The method of claim 6 , wherein the second treatment is a dietary or pharmaceutical therapy.

8. The method of claim 7 , wherein the dietary therapy is a gluten-free diet.

9. The method of claim 1 , wherein the probiotic bacterium Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 is non-replicating.

10. The method of claim 9 , wherein the probiotic bacterium Lactobacillus paracasei CBA L74, International Depository Accession Number LMG P-24778 is dead.

11. The method of claim 1 , wherein the composition further comprises a food product or a pharmaceutical carrier.

12. A method of treating a subject having a gluten-related disorder, the method comprising:

administering to the subject an effective amount of a composition comprising a fermented food product, wherein the fermented food product has been fermented by probiotic bacterium Lactobacillus paracasei CBA L74, deposited at the Belgian Coordinated Collections of Micro-organisms (BCCM) Laboratorium voor Microbiologie (LMG) and having International Depository Accession Number LMG P-24778, and the fermented food product reduces a symptom of gliadin peptide toxicity.

13. The method of claim 12 , wherein the probiotic bacterium Lactobacillus paracasei CBA L74 in the composition is dead or has been rendered incapable of cell division.

14. The method of claim 12 , wherein the food product is a dairy product or a cereal product.

15. The method of claim 12 , wherein the composition further comprises a pharmaceutical carrier.

16. The method of claim 12 , wherein the gliadin peptide is an α-gliadin peptide.

17. The method of claim 16 , wherein the α-gliadin peptide has an amino acid sequence selected from the group consisting of LGQQQPFPPQQPY (SEQ ID NO: 1); QLQPFPQPQLPY (SEQ ID NO: 2); LGQQQPFPPQQPYPQPQPF (SEQ ID NO: 3); and LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 4).

18. The method of claim 12 , wherein the gluten-related disorder is celiac disease or gluten sensitivity.

19. The method of claim 12 , wherein the symptom of gliadin peptide toxicity comprises at least one of inflammation, an autoimmune reaction, a gastrointestinal symptom, weight loss, anemia, osteoporosis, arthritis, infertility, peripheral neuropathy, and liver failure.

20. The method of claim 12 , further comprising a step of administering a second treatment for the gluten-related disorder.

21. The method of claim 20 , wherein the second treatment is a dietary or pharmaceutical therapy.

22. The method of claim 21 , wherein the dietary therapy is a gluten-free diet.

23. A method of treating a subject having a gluten-related disorder, the method comprising:

administering to the subject an effective amount of a composition comprising a culture supernatant of probiotic bacterium Lactobacillus paracasei CBA L74, deposited at the Belgian Coordinated Collections of Micro-organisms (BCCM) Laboratorium voor Microbiologie (LMG) and having International Depository Accession Number LMG P-24778, wherein the culture supernatant reduces a symptom of gliadin peptide toxicity in a subject having a gluten-related disorder, and

the culture supernatant comprises Lactobacillus paracasei CBA L74 cells and/or one or more sub-cellular bacterial components from Lactobacillus paracasei CBA L74 cells, wherein any Lactobacillus paracasei CBA L74 cells present in the culture supernatant are dead or have been rendered incapable of cell division.

24. The method of claim 23 , wherein the composition further comprises a food product or a pharmaceutical carrier.

25. The method of claim 23 , wherein the gliadin peptide is an α-gliadin peptide.

26. The method of claim 25 , wherein the α-gliadin peptide has an amino acid sequence selected from the group consisting of LGQQQPFPPQQPY (SEQ ID NO: 1); QLQPFPQPQLPY (SEQ ID NO: 2); LGQQQPFPPQQPYPQPQPF (SEQ ID NO: 3); and LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 4).

27. The method of claim 23 , wherein the gluten-related disorder is celiac disease or gluten sensitivity.

28. The method of claim 23 , wherein the symptom of gliadin peptide toxicity comprises at least one of inflammation, an autoimmune reaction, a gastrointestinal symptom, weight loss, anemia, osteoporosis, arthritis, infertility, peripheral neuropathy, and liver failure.

29. The method of claim 23 , further comprising administering a second treatment for the gluten-related disorder.

30. The method of claim 29 , wherein the second treatment is a dietary or pharmaceutical therapy.

31. The method of claim 30 , wherein the dietary therapy is a gluten-free diet.